PURPOSE: To determine the prevalence of adenomatous and hyperplastic polyps in a large cohort of individuals with a germline mutation in a mismatch repair (MMR) gene, the major genetic determinant of hereditary nonpolyposis colorectal cancer (HNPCC). These prevalences have been estimated previously in smaller studies, and the results have been found to be variable. PATIENTS AND METHODS: Colorectal Adenoma/Carcinoma Prevention Programme 2 trial is a chemoprevention trial in people classified as having HNPCC. The 695 patients with a proven germline MMR mutation and documented screening history before the chemoprevention study were the focus of this study. The number, histology, size, and location of polyps found at the participants' first ever colonoscopy were analyzed in a cross-sectional study. RESULTS: Seventy-four patients (10.6%) were found to have at least one adenoma at first colonoscopy, whereas 37 (5.3%) had at least one hyperplastic polyp. The frequency of an adenoma at first colonoscopy increased from 5.0% (95% CI, 2.8% to 8.3%) in patients younger than 35 years old to 18.9% (95% CI, 9.4% to 32.0%) in patients age at least 55 years (P = .0001 for trend). No such trend was observed for hyperplastic polyps. No sex differences were found for either type of polyp. A marginal association was found between the co-occurrence of adenomas and hyperplastic polyps. Adenomas tended to be more proximally distributed through the colon, whereas hyperplastic polyps tended to be located in the distal colon. CONCLUSION: Adenoma prevalence increases with age among MMR mutation carriers, whereas hyperplastic polyp prevalence is consistent. No sex differences were observed for either type of lesion.
PURPOSE: To determine the prevalence of adenomatous and hyperplastic polyps in a large cohort of individuals with a germline mutation in a mismatch repair (MMR) gene, the major genetic determinant of hereditary nonpolyposis colorectal cancer (HNPCC). These prevalences have been estimated previously in smaller studies, and the results have been found to be variable. PATIENTS AND METHODS: Colorectal Adenoma/Carcinoma Prevention Programme 2 trial is a chemoprevention trial in people classified as having HNPCC. The 695 patients with a proven germline MMR mutation and documented screening history before the chemoprevention study were the focus of this study. The number, histology, size, and location of polyps found at the participants' first ever colonoscopy were analyzed in a cross-sectional study. RESULTS: Seventy-four patients (10.6%) were found to have at least one adenoma at first colonoscopy, whereas 37 (5.3%) had at least one hyperplastic polyp. The frequency of an adenoma at first colonoscopy increased from 5.0% (95% CI, 2.8% to 8.3%) in patients younger than 35 years old to 18.9% (95% CI, 9.4% to 32.0%) in patients age at least 55 years (P = .0001 for trend). No such trend was observed for hyperplastic polyps. No sex differences were found for either type of polyp. A marginal association was found between the co-occurrence of adenomas and hyperplastic polyps. Adenomas tended to be more proximally distributed through the colon, whereas hyperplastic polyps tended to be located in the distal colon. CONCLUSION:Adenoma prevalence increases with age among MMR mutation carriers, whereas hyperplastic polyp prevalence is consistent. No sex differences were observed for either type of lesion.
Authors: H J Järvinen; M Aarnio; H Mustonen; K Aktan-Collan; L A Aaltonen; P Peltomäki; A De La Chapelle; J P Mecklin Journal: Gastroenterology Date: 2000-05 Impact factor: 22.682
Authors: Isis Dove-Edwin; Andrea E de Jong; Joanna Adams; David Mesher; Lara Lipton; Peter Sasieni; Hans F A Vasen; Huw J W Thomas Journal: Gastroenterology Date: 2006-06 Impact factor: 22.682
Authors: J C Clark; Y Collan; T J Eide; J Estève; S Ewen; N M Gibbs; O M Jensen; E Koskela; R MacLennan; J G Simpson Journal: Int J Cancer Date: 1985-08-15 Impact factor: 7.396
Authors: K Chang; J A Willis; J Reumers; M W Taggart; F A San Lucas; S Thirumurthi; P Kanth; D A Delker; C H Hagedorn; P M Lynch; L M Ellis; E T Hawk; P A Scheet; S Kopetz; J Arts; J Guinney; R Dienstmann; E Vilar Journal: Ann Oncol Date: 2018-10-01 Impact factor: 32.976
Authors: Luis G Carvajal-Carmona; Ann G Zauber; Angela M Jones; Kimberley Howarth; Jiping Wang; Timothy Cheng; Robert Riddell; Angel Lanas; Dion Morton; Monica M Bertagnolli; Ian Tomlinson Journal: Gastroenterology Date: 2012-09-19 Impact factor: 22.682
Authors: Douglas K Rex; Dennis J Ahnen; John A Baron; Kenneth P Batts; Carol A Burke; Randall W Burt; John R Goldblum; José G Guillem; Charles J Kahi; Matthew F Kalady; Michael J O'Brien; Robert D Odze; Shuji Ogino; Susan Parry; Dale C Snover; Emina Emilia Torlakovic; Paul E Wise; Joanne Young; James Church Journal: Am J Gastroenterol Date: 2012-06-19 Impact factor: 10.864
Authors: Tuan A Dinh; Benjamin I Rosner; James C Atwood; C Richard Boland; Sapna Syngal; Hans F A Vasen; Stephen B Gruber; Randall W Burt Journal: Cancer Prev Res (Phila) Date: 2010-11-18
Authors: Maria Simona Pino; Mari Mino-Kenudson; Bernadette Mandes Wildemore; Aniruddha Ganguly; Julie Batten; Isabella Sperduti; Anthony John Iafrate; Daniel C Chung Journal: J Mol Diagn Date: 2009-03-26 Impact factor: 5.568